Peptidoglycan recognition protein 2

Peptidoglycan recognition protein 2 (PGLYRP2) is an enzyme (EC 3.5.1.28), N-acetylmuramoyl-L-alanine amidase (NAMLAA), that hydrolyzes bacterial cell wall peptidoglycan and is encoded by the PGLYRP2 gene.[1][2][3][4][5][6]

PGLYRP2
Identifiers
AliasesPGLYRP2, HMFT0141, PGLYRPL, PGRP-L, PGRPL, TAGL-like, tagL, tagL-alpha, tagl-beta, peptidoglycan recognition protein 2
External IDsOMIM: 608199; MGI: 1928099; HomoloGene: 49671; GeneCards: PGLYRP2; OMA:PGLYRP2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

114770

57757

Ensembl

ENSG00000161031

ENSMUSG00000079563

UniProt

Q96PD5

Q8VCS0

RefSeq (mRNA)

NM_052890
NM_001363546

NM_001271476
NM_001271477
NM_001271478
NM_001271479
NM_021319

RefSeq (protein)

NP_443122
NP_001350475

NP_001258405
NP_001258406
NP_001258407
NP_001258408
NP_067294

Location (UCSC)Chr 19: 15.47 – 15.5 MbChr 17: 32.63 – 32.64 Mb
PubMed search[9][10]
Wikidata
View/Edit HumanView/Edit Mouse

Discovery

The N-acetylmuramoyl-L-alanine amidase enzymatic activity was first observed in human and mouse serum in 1981 by Branko Ladešić and coworkers.[11] The enzyme (abbreviated NAMLAA) was then purified from human serum by this[12] and other groups.[13][14][15][16] The sequence of 15 N-terminal amino acids of NAMLAA was identified,[15] but the cDNA for the protein was not cloned and the gene encoding NAMLAA was not known.

In 2000, Dan Hultmark and coworkers discovered a family of 12 Peptidoglycan Recognition Protein (PGRP) genes in Drosophila melanogaster and by homology searches of available human and mouse sequences predicted the presence of long forms of human and mouse PGRPs, which they named PGRP-L by analogy to long forms of insect PGRPs.[17]

In 2001, Roman Dziarski and coworkers discovered and cloned three human PGRPs, named PGRP-L, PGRP-Iα, and PGRP-Iβ (for long and intermediate size transcripts),[1] and established that human genome codes for a family of 4 PGRPs: PGRP-S (short PGRP)[18] and PGRP-L, PGRP-Iα, and PGRP-Iβ.[1] Subsequently, the Human Genome Organization Gene Nomenclature Committee changed the gene symbols of PGRP-S, PGRP-L, PGRP-Iα, and PGRP-Iβ to PGLYRP1 (peptidoglycan recognition protein 1), PGLYRP2 (peptidoglycan recognition protein 2), PGLYRP3 (peptidoglycan recognition protein 3), and PGLYRP4 (peptidoglycan recognition protein 4), respectively, and this nomenclature is currently also used for other mammalian PGRPs. Sergei Kiselev and coworkers also independently cloned mouse PGLYRP2 (which they named TagL).[2][19]

Location of human PGLYRP2 gene on chromosome 19 and schematic gene, cDNA, and protein structures with exons, introns, and protein domains indicated.

In 2003 Håkan Steiner and coworkers[3] and Roman Dziarski and coworkers[4] discovered that mouse[3] and human[4] PGLYRP2 (PGRP-L) proteins encoded by the mouse and human PGLYRP2 genes are N-acetylmuramoyl-L-alanine amidases. Recombinant and native human PGLYRP2 proteins were then further shown to be identical with the previously identified and purified serum NAMLAA.[20]

Tissue distribution and secretion

Human and mouse PGLYRP2 is constitutively expressed in the adult and fetal liver, from where it is secreted into the blood.[1][3][20][21][22] PGLYRP2 (NAMLAA) is present in human plasma at 100 to 200 μg/mL[16][23] and at lower concentrations in saliva, milk, cerebrospinal fluid, and synovial fluid.[23] PGLYRP2 is also expressed to a much lower level in the colon, lymph nodes, spleen, thymus, heart, and polymorphonuclear leukocyte granules.[1][24][25] PGLYRP2 is differentially expressed in the developing brain and this expression is influenced by the intestinal microbiome.[26] Bacteria and cytokines induce low level of PGLYRP2 expression in the skin and gastrointestinal and oral epithelial cells,[22][27][28][29][30] and also in intestinal intraepithelial T lymphocytes, dendritic cells, NK (natural killer) cells, and inflammatory macrophages.[31][32] Some mammals, e.g. pigs, express multiple splice forms of PGLYRP2 with differential expression.[33]

Bacteria and cytokines induce expression of PGLYRP2 in epithelial cells through the p38 mitogen activated protein kinase (MAPK) and IRAK1 (interleukin-1 receptor-associated kinase 1) signaling pathways.[27][30] Constitutive and induced expression of PGLYRP2 is controlled by different transcription factors whose binding sequences are located in different regions of the PGLYRP2 promoter.[22] Constitutive expression of PGLYRP2 in hepatocytes is regulated by transcription factors c-Jun and ATF2 (activating transcription factor 2) through sequences in the proximal region of the promoter.[22] Induced expression of PGLYRP2 in keratinocytes is regulated by transcription factors NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and Sp1 (specificity protein 1) through sequences in the distal region of the promoter.[22]

Structure

PGLYRP2 has one canonical carboxy-terminal catalytic peptidoglycan-binding type 2 amidase domain (also known as a PGRP domain) with predicted peptidoglycan-binding and catalytic cleft with walls formed by α-helices and the floor by a β-sheet.[1][3][34] PGLYRP2 also has a long N-terminal segment that comprises two thirds of the PGLYRP2 sequence, has two hydrophobic regions, is not found in other mammalian PGLYRP1, PGLYRP3, and PGLYRP4 and in invertebrate PGRPs, and is unique with no identifiable functional motifs or domains.[1][3][34] The C-terminal segment is also longer than in other mammalian PGLYRPs.[1][3][34] PGLYRP2 has two pairs of cysteines in the PGRP domain that are conserved in all human PGRPs and are predicted to form two disulfide bonds.[1] Human PGLYRP2 is glycosylated[13][15] and secreted,[12][13][14][15][16][20][21] and forms non-disulfide-linked homodimers.[15]

PGLYRP2, similar to all other amidase-active PGRPs (invertebrate and vertebrate), has a conserved Zn2+-binding site in the peptidoglycan-binding cleft, which is also present in bacteriophage type 2 amidases and consists of two histidines, one tyrosine, and one cysteine (His411, Tyr447, His522, Cys530 in human PGLYRP2).[4]

Functions

The PGLYRP2 protein plays an important role in the innate immune responses.

Peptidoglycan binding and hydrolysis

PGLYRP2 is an enzyme (EC 3.5.1.28), N-acetylmuramoyl-L-alanine amidase, that binds and hydrolyzes bacterial cell wall peptidoglycan.[1][3][4][11][12][13][14][15][16][35] Peptidoglycan is the main component of bacterial cell wall and is a polymer of β(1-4)-linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) with MurNAc-attached short peptides, typically composed of alternating L and D amino acids, that cross-link the adjacent polysaccharide chains.

PGLYRP2 hydrolyzes the amide bond between the MurNAc and L-Ala, the first amino acid in the stem peptide.[3][4][11][12] This hydrolysis separates the crosslinking peptides from the polysaccharide chains and solubilizes cross-linked bacterial peptidoglycan into uncross-linked polysaccharide chains.[4] The minimal peptidoglycan fragment hydrolyzed by PGLYRP2 is MurNAc-tripeptide.[4]

The peptidoglycan-binding site, which is also the amidase catalytic domain, is located in the C-terminal PGRP domain. This PGRP domain is sufficient for the enzymatic activity of PGLYRP2, although this activity of the isolated C-terminal fragment is diminished compared with the entire PGLYRP2 molecule.[4] Zn2+ and Zn2+-binding amino acids (His411, Tyr447, and Cys530 in human PGLYRP2) are required for the amidase activity.[4] Cys419 in human PGLYRP2, which is broadly conserved in invertebrate and vertebrate PRGPs, forms a disulfide bond with Cys425 (in human PGLYRP2) and is required for the amidase activity, as this disulfide bond is essential for the structural integrity of the PGRP domain.[4] Cys530 is conserved in all amidase-active vertebrate and invertebrate PGRPs, whereas non-catalytic PGRPs (including mammalian PGLYRP1, PGLYRP3, and PGLYRP4) have serine in this position,[1] and thus the presence of Cys or Ser in this position can be used to predict amidase activity of PGRPs.[4] However, Cys530 and seven other amino acids that are all required for the amidase activity of PGRPs are not sufficient for the amidase activity, which requires additional so far unidentified amino acids.[4]

Defense against infections

PGLYRP2 plays a limited role in host defense against infections. PGLYRP2-deficient mice are more sensitive to Pseudomonas aeruginosa-induced keratitis[36] and Streptococcus pneumoniae-induced pneumonia and sepsis.[37] However, PGLYRP2-deficient mice did not show a changed susceptibility to systemic Escherichia coli, Staphylococcus aureus, and Candida albicans infections[21] or intestinal Salmonella enterica infection,[32] although the latter was accompanied by increased inflammation in the cecum.[31]

Although PGLYRP2 is not directly bacteriolytic,[4] it has antibacterial activity against both Gram-positive and Gram-negative bacteria and Chlamydia trachomatis.[38]

Maintaining microbiome

Mouse PGLYRP2 plays a role in maintaining healthy microbiome, as PGLYRP2-deficient mice have significant changes in the composition of their intestinal microbiome, which affect their sensitivity to colitis.[39][40]

Effects on inflammation

PGLYRP2 directly and indirectly affects inflammation and plays a role in maintaining anti- and pro-inflammatory homeostasis in the intestine, skin, joints, and brain.

Hydrolysis of peptidoglycan by PGLYRP2 diminishes peptidoglycan's pro-inflammatory activity.[31][41] This effect is likely due to amidase activity of PGLYRP2, which separates the stem peptide from MurNAc in peptidoglycan and destroys the motif required for the peptidoglycan-induced activation of NOD2 (nucleotide-binding oligomerization domain-containing protein 2), one of the proinflammatory peptidoglycan receptors.[31]

PGLYRP2-deficient mice are more susceptible than wild type mice to dextran sodium sulfate (DSS)-induced colitis, which indicates that PGLYRP2 protects mice from DSS-induced colitis.[39] Intestinal microbiome is important for this protection, because this increased sensitivity to colitis could be transferred to wild type germ-free mice by microbiome transplant from PGLYRP2-deficient mice.[39]

PGLYRP2-deficient mice are more susceptible than wild type mice to the development of experimentally induced psoriasis-like inflammation,[42] which indicates that PGLYRP2 is anti-inflammatory and protects mice from this type of skin inflammation. This pro-inflammatory effect in PGLYRP2-deficient mice is due to the increased numbers and activity of T helper 17 (Th17) cells and decreased numbers of T regulatory (Treg) cells.[42] PGLYRP2-deficient mice are more susceptible than wild type mice to S. enterica-induced intestinal inflammation,[32] which indicates that PGLYRP2 also has anti-inflammatory effect in the intestinal tract.

However, PGLYRP2 also has opposite effects. PGLYRP2-deficient mice are more resistant than wild type mice to the development of arthritis induced by systemic administration of peptidoglycan or MurNAc-L-Ala-D-isoGln peptidoglycan fragment (muramyl dipeptide, MDP).[43] In this model, PGLYRP2 is required for the production of chemokines and cytokines that attract neutrophils to the arthritic joints.[43] PGLYRP2-deficient mice are also more resistant than wild type mice to bacterially induced keratitis[36] and inflammation in S. pneumoniae-induced lung infection.[37] Moreover, PGLYRP2-deficient mice are more resistant to weight loss in a model of chemotherapy-induced gastrointestinal toxicity, which indicates that in wild type mice PGLYRP2 contributes to the chemotherapy-induced weight loss.[44] These results indicate that under certain conditions PGLYRP2 has pro-inflammatory effects.[36][37][43]

PGLYRP2-deficient mice also show higher sociability and decreased levels of anxiety-like behaviors compared with wild type mice, which indicate that PGLYRP2 affects behavior in mice.[26][45]

Medical relevance

Genetic PGLYRP2 variants or changed expression of PGLYRP2 are associated with some diseases. Patients with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, have significantly more frequent missense variants in PGLYRP2 gene (and also in the other three PGLYRP genes) than healthy controls.[34] These results suggest that PGLYRP2 protects humans from these inflammatory diseases, and that mutations in PGLYRP2 gene are among the genetic factors predisposing to these diseases. PGLYRP2 variants are also associated with esophageal squamous cell carcinoma[46] and Parkinson's disease.[47][48][49]

Increased serum PGLYRP2 levels are present in patients with systemic lupus erythematosus and correlate with disease activity index, renal damage, and abnormal lipid profile.[50]

Decreased expression of PGLYRP2 is found in HIV-associated tuberculosis,[51] drug-sensitive tuberculosis,[52] Lyme disease,[53] hepatocellular carcinoma,[54] and myocardial infarction.[55]

Autoantibodies to PGLYRP2 are significantly increased in patients with rheumatoid arthritis.[56]

See also

References

  1. ^ a b c d e f g h i j k Liu C, Xu Z, Gupta D, Dziarski R (September 2001). "Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules". The Journal of Biological Chemistry. 276 (37): 34686–94. doi:10.1074/jbc.M105566200. PMID 11461926. S2CID 44619852.
  2. ^ a b Kibardin AV, Mirkina II, Korneeva EA, Gnuchev NV, Georgiev GP, Kiselev SL (May 2000). "Molecular cloning of a new mouse gene tagL containing a lysozyme-like domain". Doklady Biochemistry. 372 (1–6): 103–5. PMID 10935177.
  3. ^ a b c d e f g h i Gelius E, Persson C, Karlsson J, Steiner H (July 2003). "A mammalian peptidoglycan recognition protein with N-acetylmuramoyl-L-alanine amidase activity". Biochemical and Biophysical Research Communications. 306 (4): 988–94. doi:10.1016/s0006-291x(03)01096-9. PMID 12821140.
  4. ^ a b c d e f g h i j k l m n Wang ZM, Li X, Cocklin RR, Wang M, Wang M, Fukase K, et al. (December 2003). "Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase". The Journal of Biological Chemistry. 278 (49): 49044–52. doi:10.1074/jbc.M307758200. PMID 14506276. S2CID 35373818.
  5. ^ "PGLYRP2 peptidoglycan recognition protein 2 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2020-11-02.
  6. ^ "Pglyrp2 peptidoglycan recognition protein 2 [Mus musculus (house mouse)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2020-11-03.
  7. ^ a b c GRCh38: Ensembl release 89: ENSG00000161031 – Ensembl, May 2017
  8. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000079563 – Ensembl, May 2017
  9. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  10. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  11. ^ a b c Ladesić B, Tomasić J, Kveder S, Hrsak I (November 1981). "The metabolic fate of 14C-labeled immunoadjuvant peptidoglycan monomer. II. In vitro studies". Biochimica et Biophysica Acta. 678 (1): 12–7. doi:10.1016/0304-4165(81)90042-8. PMID 6118181.
  12. ^ a b c d Valinger Z, Ladesić B, Tomasić J (February 1982). "Partial purification and characterization of N-acetylmuramyl-L-alanine amidase from human and mouse serum". Biochimica et Biophysica Acta. 701 (1): 63–71. doi:10.1016/0167-4838(82)90313-2. PMID 6120007.
  13. ^ a b c d Mollner S, Braun V (December 1984). "Murein hydrolase (N-acetyl-muramyl-L-alanine amidase) in human serum". Archives of Microbiology. 140 (2–3): 171–7. Bibcode:1984ArMic.140..171M. doi:10.1007/BF00454921. PMID 6152147. S2CID 28541212.
  14. ^ a b c Vanderwinkel E, de Vlieghere M, de Pauw P, Cattalini N, Ledoux V, Gigot D, ten Have JP (July 1990). "Purification and characterization of N-acetylmuramoyl-L-alanine amidase from human serum". Biochimica et Biophysica Acta. 1039 (3): 331–8. doi:10.1016/0167-4838(90)90267-j. PMID 1974148.
  15. ^ a b c d e f De Pauw P, Neyt C, Vanderwinkel E, Wattiez R, Falmagne P (June 1995). "Characterization of human serum N-acetylmuramyl-L-alanine amidase purified by affinity chromatography". Protein Expression and Purification. 6 (3): 371–8. doi:10.1006/prep.1995.1049. PMID 7663175.
  16. ^ a b c d Hoijer MA, Melief MJ, Keck W, Hazenberg MP (February 1996). "Purification and characterization of N-acetylmuramyl-L-alanine amidase from human plasma using monoclonal antibodies". Biochimica et Biophysica Acta (BBA) - General Subjects. 1289 (1): 57–64. doi:10.1016/0304-4165(95)00136-0. hdl:1765/62308. PMID 8605233.
  17. ^ Werner T, Liu G, Kang D, Ekengren S, Steiner H, Hultmark D (December 2000). "A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster". Proceedings of the National Academy of Sciences of the United States of America. 97 (25): 13772–7. Bibcode:2000PNAS...9713772W. doi:10.1073/pnas.97.25.13772. PMC 17651. PMID 11106397.
  18. ^ Kang D, Liu G, Lundström A, Gelius E, Steiner H (August 1998). "A peptidoglycan recognition protein in innate immunity conserved from insects to humans". Proceedings of the National Academy of Sciences of the United States of America. 95 (17): 10078–82. Bibcode:1998PNAS...9510078K. doi:10.1073/pnas.95.17.10078. PMC 21464. PMID 9707603.
  19. ^ Kibardin AV, Mirkina II, Baranova EV, Zakeyeva IR, Georgiev GP, Kiselev SL (February 2003). "The differentially spliced mouse tagL gene, homolog of tag7/PGRP gene family in mammals and Drosophila, can recognize Gram-positive and Gram-negative bacterial cell wall independently of T phage lysozyme homology domain". Journal of Molecular Biology. 326 (2): 467–74. doi:10.1016/s0022-2836(02)01401-8. PMID 12559914.
  20. ^ a b c Zhang Y, van der Fits L, Voerman JS, Melief MJ, Laman JD, Wang M, et al. (August 2005). "Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1752 (1): 34–46. doi:10.1016/j.bbapap.2005.07.001. PMID 16054449.
  21. ^ a b c Xu M, Wang Z, Locksley RM (September 2004). "Innate immune responses in peptidoglycan recognition protein L-deficient mice". Molecular and Cellular Biology. 24 (18): 7949–57. doi:10.1128/MCB.24.18.7949-7957.2004. PMC 515053. PMID 15340057.
  22. ^ a b c d e Li X, Wang S, Wang H, Gupta D (July 2006). "Differential expression of peptidoglycan recognition protein 2 in the skin and liver requires different transcription factors". The Journal of Biological Chemistry. 281 (30): 20738–48. doi:10.1074/jbc.M601017200. PMID 16714290. S2CID 22076229.
  23. ^ a b Vanderwinkel E, de Pauw P, Philipp D, Ten Have JP, Bainter K (February 1995). "The human and mammalian N-acetylmuramyl-L-alanine amidase: distribution, action on different bacterial peptidoglycans, and comparison with the human lysozyme activities". Biochemical and Molecular Medicine. 54 (1): 26–32. doi:10.1006/bmme.1995.1004. PMID 7551813.
  24. ^ Hoijer MA, Melief MJ, Calafat J, Roos D, van den Beemd RW, van Dongen JJ, Hazenberg MP (August 1997). "Expression and intracellular localization of the human N-acetylmuramyl-L-alanine amidase, a bacterial cell wall-degrading enzyme". Blood. 90 (3): 1246–54. doi:10.1182/blood.V90.3.1246. PMID 9242559.
  25. ^ Hoijer MA, de Groot R, van Lieshout L, Jacobs BC, Melief MJ, Hazenberg MP (January 1998). "Differences in N-acetylmuramyl-L-alanine amidase and lysozyme in serum and cerebrospinal fluid of patients with bacterial meningitis". The Journal of Infectious Diseases. 177 (1): 102–6. doi:10.1086/513815. PMID 9419176. S2CID 22133917.
  26. ^ a b Arentsen T, Qian Y, Gkotzis S, Femenia T, Wang T, Udekwu K, et al. (February 2017). "The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior". Molecular Psychiatry. 22 (2): 257–266. doi:10.1038/mp.2016.182. PMC 5285465. PMID 27843150.
  27. ^ a b Wang H, Gupta D, Li X, Dziarski R (November 2005). "Peptidoglycan recognition protein 2 (N-acetylmuramoyl-L-Ala amidase) is induced in keratinocytes by bacteria through the p38 kinase pathway". Infection and Immunity. 73 (11): 7216–25. doi:10.1128/IAI.73.11.7216-7225.2005. PMC 1273900. PMID 16239516.
  28. ^ Lu X, Wang M, Qi J, Wang H, Li X, Gupta D, Dziarski R (March 2006). "Peptidoglycan recognition proteins are a new class of human bactericidal proteins". The Journal of Biological Chemistry. 281 (9): 5895–907. doi:10.1074/jbc.M511631200. PMID 16354652. S2CID 21943426.
  29. ^ Uehara A, Sugawara Y, Kurata S, Fujimoto Y, Fukase K, Kusumoto S, et al. (May 2005). "Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells". Cellular Microbiology. 7 (5): 675–86. doi:10.1111/j.1462-5822.2004.00500.x. PMID 15839897. S2CID 20544993.
  30. ^ a b Scholz GM, Heath JE, Aw J, Reynolds EC (September 2018). "Regulation of the Peptidoglycan Amidase PGLYRP2 in Epithelial Cells by Interleukin-36γ". Infection and Immunity. 86 (9). doi:10.1128/IAI.00384-18. PMC 6105881. PMID 29914927.
  31. ^ a b c d Duerr CU, Salzman NH, Dupont A, Szabo A, Normark BH, Normark S, et al. (May 2011). "Control of intestinal Nod2-mediated peptidoglycan recognition by epithelium-associated lymphocytes". Mucosal Immunology. 4 (3): 325–34. doi:10.1038/mi.2010.71. PMID 20980996. S2CID 10298644.
  32. ^ a b c Lee J, Geddes K, Streutker C, Philpott DJ, Girardin SE (August 2012). "Role of mouse peptidoglycan recognition protein PGLYRP2 in the innate immune response to Salmonella enterica serovar Typhimurium infection in vivo". Infection and Immunity. 80 (8): 2645–54. doi:10.1128/IAI.00168-12. PMC 3434585. PMID 22615249.
  33. ^ Sang Y, Ramanathan B, Ross CR, Blecha F (November 2005). "Gene silencing and overexpression of porcine peptidoglycan recognition protein long isoforms: involvement in beta-defensin-1 expression". Infection and Immunity. 73 (11): 7133–41. doi:10.1128/IAI.73.11.7133-7141.2005. PMC 1273832. PMID 16239507.
  34. ^ a b c d Zulfiqar F, Hozo I, Rangarajan S, Mariuzza RA, Dziarski R, Gupta D (2013). "Genetic Association of Peptidoglycan Recognition Protein Variants with Inflammatory Bowel Disease". PLOS ONE. 8 (6): e67393. Bibcode:2013PLoSO...867393Z. doi:10.1371/journal.pone.0067393. PMC 3686734. PMID 23840689.
  35. ^ "Reactome | PGLYRP2 hydrolyzes bacterial peptidoglycan". reactome.org. Retrieved 2020-11-03.
  36. ^ a b c Gowda RN, Redfern R, Frikeche J, Pinglay S, Foster JW, Lema C, et al. (2015). "Functions of Peptidoglycan Recognition Proteins (Pglyrps) at the Ocular Surface: Bacterial Keratitis in Gene-Targeted Mice Deficient in Pglyrp-2, -3 and -4". PLOS ONE. 10 (9): e0137129. Bibcode:2015PLoSO..1037129G. doi:10.1371/journal.pone.0137129. PMC 4558058. PMID 26332373.
  37. ^ a b c Dabrowski AN, Conrad C, Behrendt U, Shrivastav A, Baal N, Wienhold SM, et al. (2019). "Streptococcus pneumoniae Infection". Frontiers in Microbiology. 10: 199. doi:10.3389/fmicb.2019.00199. PMC 6389715. PMID 30837960.
  38. ^ Bobrovsky P, Manuvera V, Polina N, Podgorny O, Prusakov K, Govorun V, Lazarev V (July 2016). "Recombinant Human Peptidoglycan Recognition Proteins Reveal Antichlamydial Activity". Infection and Immunity. 84 (7): 2124–2130. doi:10.1128/IAI.01495-15. PMC 4936355. PMID 27160295.
  39. ^ a b c Saha S, Jing X, Park SY, Wang S, Li X, Gupta D, Dziarski R (August 2010). "Peptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gamma". Cell Host & Microbe. 8 (2): 147–62. doi:10.1016/j.chom.2010.07.005. PMC 2998413. PMID 20709292.
  40. ^ Dziarski R, Park SY, Kashyap DR, Dowd SE, Gupta D (2016). "Pglyrp-Regulated Gut Microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii Enhance and Alistipes finegoldii Attenuates Colitis in Mice". PLOS ONE. 11 (1): e0146162. Bibcode:2016PLoSO..1146162D. doi:10.1371/journal.pone.0146162. PMC 4699708. PMID 26727498.
  41. ^ Hoijer MA, Melief MJ, Debets R, Hazenberg MP (December 1997). "Inflammatory properties of peptidoglycan are decreased after degradation by human N-acetylmuramyl-L-alanine amidase". European Cytokine Network. 8 (4): 375–81. PMID 9459617.
  42. ^ a b Park SY, Gupta D, Hurwich R, Kim CH, Dziarski R (December 2011). "Peptidoglycan recognition protein Pglyrp2 protects mice from psoriasis-like skin inflammation by promoting regulatory T cells and limiting Th17 responses". Journal of Immunology. 187 (11): 5813–23. doi:10.4049/jimmunol.1101068. PMC 3221838. PMID 22048773.
  43. ^ a b c Saha S, Qi J, Wang S, Wang M, Li X, Kim YG, et al. (February 2009). "PGLYRP-2 and Nod2 are both required for peptidoglycan-induced arthritis and local inflammation". Cell Host & Microbe. 5 (2): 137–50. doi:10.1016/j.chom.2008.12.010. PMC 2671207. PMID 19218085.
  44. ^ Bech AS, Nexoe AB, Dubik M, Moeller JB, Soerensen GL, Holmskov U, Madsen GI, Husby S, Rathe M (2021-03-23). "Peptidoglycan Recognition Peptide 2 Aggravates Weight Loss in a Murine Model of Chemotherapy-Induced Gastrointestinal Toxicity". Frontiers in Oncology. 11. doi:10.3389/fonc.2021.635005. ISSN 2234-943X. PMC 8021894. PMID 33833993.
  45. ^ Arentsen T, Khalid R, Qian Y, Diaz Heijtz R (January 2018). "Sex-dependent alterations in motor and anxiety-like behavior of aged bacterial peptidoglycan sensing molecule 2 knockout mice". Brain, Behavior, and Immunity. 67: 345–354. doi:10.1016/j.bbi.2017.09.014. PMID 28951252. S2CID 27790787.
  46. ^ Ng D, Hu N, Hu Y, Wang C, Giffen C, Tang ZZ, et al. (October 2008). "Replication of a genome-wide case-control study of esophageal squamous cell carcinoma". International Journal of Cancer. 123 (7): 1610–5. doi:10.1002/ijc.23682. PMC 2552411. PMID 18649358.
  47. ^ Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, et al. (August 2014). "Peptidoglycan recognition protein genes and risk of Parkinson's disease". Movement Disorders. 29 (9): 1171–80. doi:10.1002/mds.25895. PMC 4777298. PMID 24838182.
  48. ^ Gorecki AM, Bakeberg MC, Theunissen F, Kenna JE, Hoes ME, Pfaff AL, Akkari PA, Dunlop SA, Kõks S, Mastaglia FL, Anderton RS (2020-11-17). "Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease". Frontiers in Aging Neuroscience. 12. doi:10.3389/fnagi.2020.603849. ISSN 1663-4365. PMC 7718032. PMID 33328979.
  49. ^ Luan M, Jin J, Wang Y, Li X, Xie A (April 2022). "Association of PGLYRP2 gene polymorphism and sporadic Parkinson's disease in northern Chinese Han population". Neuroscience Letters. 775: 136547. doi:10.1016/j.neulet.2022.136547. PMID 35218888. S2CID 247028433.
  50. ^ Li H, Meng D, Jia J, Wei H (December 2021). "PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus". Lipids in Health and Disease. 20 (1): 95. doi:10.1186/s12944-021-01515-8. ISSN 1476-511X. PMC 8404349. PMID 34461924.
  51. ^ Achkar JM, Cortes L, Croteau P, Yanofsky C, Mentinova M, Rajotte I, et al. (September 2015). "Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals". eBioMedicine. 2 (9): 1160–8. doi:10.1016/j.ebiom.2015.07.039. PMC 4588417. PMID 26501113.
  52. ^ Chen J, Han YS, Yi WJ, Huang H, Li ZB, Shi LY, Wei LL, Yu Y, Jiang TT, Li JC (November 2020). "Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug-resistant tuberculosis based on data-independent acquisition and targeted proteomics". Journal of Cellular and Molecular Medicine. 24 (21): 12537–12549. doi:10.1111/jcmm.15796. ISSN 1582-1838. PMC 7686995. PMID 32967043.
  53. ^ Zhou Y, Qin S, Sun M, Tang L, Yan X, Kim TK, et al. (January 2020). "Measurement of Organ-Specific and Acute-Phase Blood Protein Levels in Early Lyme Disease" (PDF). Journal of Proteome Research. 19 (1): 346–359. doi:10.1021/acs.jproteome.9b00569. PMC 7981273. PMID 31618575.
  54. ^ Yang Z, Feng J, Xiao L, Chen X, Yao Y, Li Y, et al. (May 2020). "Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma". Hepatology. 71 (5): 1626–1642. doi:10.1002/hep.30924. PMC 7318564. PMID 31479523.
  55. ^ Das AA, Choudhury KR, Jagadeeshaprasad MG, Kulkarni MJ, Mondal PC, Bandyopadhyay A (June 2020). "Proteomic analysis detects deregulated reverse cholesterol transport in human subjects with ST-segment elevation myocardial infarction". Journal of Proteomics. 222: 103796. doi:10.1016/j.jprot.2020.103796. PMID 32376501. S2CID 218532507.
  56. ^ Huang F, Liu X, Cheng Y, Sun X, Li Y, Zhao J, Cao D, Wu Q, Pan X, Deng H, Tian M, Li Z (2021-08-31). "Antibody to peptidoglycan recognition protein (PGLYRP)-2 as a novel biomarker in rheumatoid arthritis". Clinical and Experimental Rheumatology. 39 (5): 988–994. doi:10.55563/clinexprheumatol/vlvlqu. ISSN 1593-098X. PMID 33427621. S2CID 231575423.

Further reading